Dual-payload ADC
A dual-payload ADC is an ADC carrying two different poisons at once, so the tumour cannot escape by becoming resistant to one.
Programs from Sutro, Mersana, Tavotek/Adcoris (ACR335, TOP1 inhibitor + non-TOP1/non-tubulin, DAR 4+4, phase 1 in 2026), and others place two payloads with distinct mechanisms on one antibody. Rationale: TOP1-payload cross-resistance after T-DXd, sacituzumab, or Dato-DXd. Also 'dual-mechanism' ADCs pairing a cytotoxic with an immune agonist.
How it works
Orthogonal site-specific conjugation chemistries attach two payload classes at defined positions.
- Delays resistance
- Combination therapy without additive antibody dose
- Manufacturing
- Two toxicity profiles in one molecule
Latest papers
topQuery for this technology: (TITLE:"dual-payload antibody-drug conjugate" OR ABSTRACT:"dual-payload antibody-drug conjugate" OR TITLE:"dual payload ADC" OR ABSTRACT:"dual payload ADC" OR TITLE:"dual-payload ADC" OR ABSTRACT:"dual-payload ADC"). Results are unfiltered search hits about Dual-payload ADC, not a curated reading list.